PARIS, France - Novacyt (EPA:ALNOV) S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), a global provider of molecular diagnostics solutions, announced today that its subsidiary Lab21 Healthcare Ltd has pleaded guilty to health and safety violations. The plea was entered at Exeter Magistrates Court concerning historical operations at the Axminster, Devon site from June 28, 2018, to April 5, 2019.
The charges stem from an investigation by the Health and Safety Executive (HSE), with the initial announcement made on January 21, 2025. Lab 21, which is no longer active within Novacyt’s operations, has cooperated with the HSE during the investigation. Novacyt had acquired the lease for the site as part of a broader acquisition on June 28, 2018.
A sentencing hearing is scheduled for September 11, 2025, to determine the penalties Lab 21 will face. The company has stated that it will provide further updates following the sentencing.
Novacyt’s business is divided into three segments: Clinical, Instrumentation, and Research Use Only, offering a range of diagnostic products, services, and technologies across various sectors, including human and animal health, and environmental testing. The company is headquartered in France with offices in the UK, Singapore, the US, and Canada, and operates commercially in over 65 countries.
This news comes as part of a press release issued by Novacyt and is based on statements provided by the company. The outcome of the sentencing in September will likely provide closure to this chapter of the company’s history as it continues to focus on its core business segments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.